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Abstract
Development of resistance to imatinib
mesylate (IM) in chronic myeloid leukemia
(CML) patients is mediated by different mech-
anisms that can be classified as BCR-ABL
dependent or BCR-ABL independent pathways.
BCR-ABL dependent mechanisms are most fre-
quently associated with point mutations in
tyrosine kinase domain (TKD) of BCR-ABL1
and also with BCR-ABL gene amplification.
Many different types and frequencies of muta-
tions have been reported in different studies,
probably due to the different composition of
study cohorts. Since no reports are available
from Malaysia, this study was undertaken to
investigate the frequency and pattern of BCR-
ABL kinase domain mutations using dHPLC
followed by sequencing, and also status of
BCR-ABL gene amplification using fluores-
cence in situ hybridization (FISH) on 40 IM
resistant Malaysian CML patients. Mutations
were detected in 13 patients (32.5%). Five dif-
ferent types of mutations (T315I, E255K,
Y253H, M351T, V289F) were identified in these
patients. In the remaining 27 IM resistant CML
patients, we investigated the contribution
made by BCR-ABL gene amplification, but
none of these patients showed amplification. It
is presumed that the mechanisms of resist-
ance in these 27 patients might be due to BCR-
ABL independent pathways. Different muta-
tions confer different levels of resistance and,
therefore, detection and characterization of
TKD mutations is highly important in order to
guide therapy in CML patients. 
Introduction
Imatinib mesylate (IM) is used as a front-
line therapy for chronic myeloid leukemia
(CML) as it is highly effective in the treatment
and management of Philadelphia (Ph) positive
CML patients. IM is a selective inhibitor of
tyrosine kinase that binds competitively to the
adenosine triphosphate (ATP) docking site of
tyrosine kinase proteins, including ABL itself
and the hybrid BCR-ABL proteins. It also
inhibits other tyrosine kinases, such as
platelet-derived growth factor receptors KIT
and ARG.1 As IM binds to the ATP binding site
at the tyrosine kinase active site, it inhibits
the transfer of terminal phosphate from ATP to
tyrosine residues on its substrates, thus
inhibiting the enzyme activity of the tyrosine
kinase protein semi-competitively. Mutations
in the BCR-ABL kinase domain can cause
resistance to IM by shifting its equilibrium
toward the open or active conformation. Some
other mutations interfere with a critical hydro-
gen bond that forms between the ABL 1 kinase
domain and inhibitor molecule thus impairing
the ability of the BCR-ABL protein to bind to
the inhibitor molecule.2
Even though IM has become the gold stan-
dard in front-line treatment of CML, resistance
to this drug is a daunting problem. Develop -
ment of resistance to IM has been a setback for
patients, as well as for treating physicians in
the clinical management of CML patients. A
patient with CML could display either a pri-
mary or secondary resistance to IM therapy.
Primary resistance is defined as inability to
achieve any initial landmark response, and
secondary response is defined as achieving a
good initial response but subsequently losing
any relevant response.3
Development of resistance to IM is a multi-
factorial phenomenon in patients with CML
and may be mediated by a range of different
mechanisms. However, there are 2 broad
mechanisms of resistance: BCR-ABL depend-
ent and BCR-ABL independent pathways.4,5
BCR-ABL dependent pathways have been
reported to be the most common cause of IM
resistance which commonly involve mutations
in the tyrosine kinase domain (TKD) of the
BCR-ABL gene,6 as well as amplification and
overexpression of the BCR-ABL gene locus.7
The present study was designed to clarify the
mechanisms of resistance involving BCR-ABL
dependent pathways.
So far, more than 100 mutations have been
identified in the tyrosine kinase domain of the
BCR-ABL gene.8 Different studies have report-
ed a broad range of frequencies of mutations
and this is probably due to the different compo-
sition of study cohorts. But no reports are
available from Malaysia. Apart from BCR-ABL
mutation, few studies have reported on the
amplification of the BCR-ABL gene locus that
is associated with IM resistance among CML
patients.9 In these rare cases, the presence of
multiple copies of the BCR-ABL gene in inter-
phase nuclei were reported in IM resistant
patients using fluorescence in situ hybridiza-
tion (FISH). In this study, we investigated the
frequency and pattern of BCR-ABL kinase
domain mutations using dHPLC and BCR-ABL
gene amplification by FISH on 40 Malaysian
CML patients who showed resistance to IM.
Materials and MethodsStudy subjects
The study was undertaken at Universiti
Sains Malaysia Hospital from 2008 to 2011,
after obtaining approval from the institute’s
Research and Ethics Committee. The study
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participants included 40 Philadelphia chromo-
some (Ph) positive CML patients in chronic,
accelerated or blast phase, treated for at least
six months with standard dose IM (400 mg) as
front-line treatment according to the phase II
extended access protocols, and who showed
only suboptimal response or signs of clinical
response to IM. Those CML patients who were
Ph negative, and those who did not opt for IM
treatment, were excluded from the study. The
medical records of all patients were reviewed
until June 2011. Basic demographic, disease
characteristics, and treatment management
details were collected. For each patient, diag-
nosis was confirmed by hematologic, cytoge-
netic, as well as molecular analysis. The
response to IM therapy was evaluated on the
basis of measurement of hematologic, cytoge-
netic and molecular responses. Hematologic
response was evaluated every 3rd month of
treatment and cytogenetic response was evalu-
ated every 6th month of treatment. 
According to European LeukemiaNet 2010,
complete hematologic remission would show
peripheral blood cell counts and bone marrow
morphology returning to normal with total
white blood cell count less than 10¥109/L and
platelet count less than 450¥109/L. Complete
hematologic remission was also defined by
absence of peripheral blast, immature granulo-
cytes such as promyelocytes or myelocytes, less
than 5% peripheral basophils and non-palpable
spleen.10 Cytogenetic remission was catego-
rized into complete, major, partial, minor and
non-responder groups. A total disappearance
of Ph chromosome in cytogenetic analysis con-
firmed complete cytogenetic response (CCyR)
while presence of less than 35% Ph+ cells in
bone marrow confirmed partial cytogenetic
response (PCyR). Patients with minor cytoge-
netic response showed 36-65% of Ph+ cells in
bone marrow while those who showed 66-95%
Ph+ chromosome positivity were categorized
as a minimal cytogenetic response group.
Patients whose bone marrow showed over 95%
Ph+ chromosome were classified as non-
responders to IM.10
Primary resistance, also known as intrinsic
resistance to IM, is defined as having no
hematologic response within three months,
having incomplete hematologic response or no
cytogenetic response within six months, and
having less than partial cytogenetic response
within 12 months. Secondary resistance or
acquired resistance is defined as evolution of
the disease from chronic phase to accelerated
phase or blast phase, loss of hematologic
response, loss of MCyR or CCyR.11
BCR-ABL mutation analysis
BCR-ABL mutation analysis was carried out
in both CML patients showing primary and
secondary resistance using the denaturing
high performance liquid chromatography
(dHPLC) method. For this, total RNA was
extracted from the peripheral blood using the
QIAamp RNA blood mini extraction kit (QIA-
GEN, Germany) according to the manufactur-
er’s instructions with a slight modification, fol-
lowed by cDNA synthesis using the cDNA
Synthesis kit (Bioline, UK) with a slightly
modified protocol. Subsequently, amplification
of 3 overlapping fragments covering the entire
kinase domain was generated by nested PCR
using the primers described by Soverini et.
al.12 The first PCR (BCR-A) with 1475 bp
amplicon length was amplified from the syn-
thesized cDNA, followed by the second PCR
(ABL-B) with 393 bp amplicon length, ampli-
fied from BCR-A amplicon. The third PCR
(ABL-C) with 482 bp amplicon length was sub-
sequently amplified, also from BCR-A ampli-
con. All PCR procedures were performed using
AccuSure Mix (Bioline, UK). 
The presence of sequence variation was then
screened by dHPLC in which PCR product was
mixed with wild-type sample (Ph positive sam-
ple with no mutation identified after sequenc-
ing) and denatured to allow the formation of
heteroduplex. This was then analyzed under the
optimum melting temperature that was deter-
mined using a melting program (http://inser-
tion.stanford.edu/melt.htm). Subsequently,
samples were screened by dHPLC (ProStar
Helix System, Varian, USA). The PCR products
of samples that showed altered dHPLC profile,
indicative of mutation, were directly sequenced
with both forward and reverse primers after
purification steps using a PCR purification kit
(QIAGEN, Germany) to characterize the muta-
tion.  Samples with mutation were then rese-
quenced for confirmation. BCR-ABL gene amplification
The samples of patients who did not show
any BCR-ABL mutations were investigated for
the progressive amplification status of the
BCR-ABL gene using FISH. For this, LSI BCR-
ABL dual fluorescent probes (Vysis Inc., USA)
which hybridize to the fusion regions and gen-
erate intense fluorescence signals were used.
The copy number of fusion signals in a mini-
mum of 200 interphase nuclei was determined
for each sample.Bioinformatics analysis
An online program (available at http://genet-
ics.bwh.harvard.edu/pph2/), PolyPhen-2, was
used to predict the potential consequence of
each mutation on the BCR-ABL protein struc-
ture. ClustalX program (version 2.0.12) was
used for multiple alignment of Homo sapiens
ABL1 protein sequence (CAA34438) with ABL1
protein sequence of chimpanzee (Pan
troglodytes; XP_001166213.2), pig (Sus scrofa;
XP_003122293.3), mouse (Mus musculus;
NP_001106174.1), rat (Rattus norvegicus;
NP_001094320.1), cow (Bos taurus;
NP_001193789.1) and chicken (Gallus gallus;
XP_001233812.1). 
Results
The demographic profile, disease character-
istics, treatment management, cytogenetic
analysis and molecular analysis of all patients
participating in the study are shown in Tables
1 and 2. The ratio of male to female CML
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Table 1. Demographic, disease characteris-
tics and treatment management of the
chronic myeloid leukemia patients.
Demographic N. patients (%)
Gender
Male 16 (40)
Female 24 (60)
Age
Median (range) 43 (17-65)
Male 41 (17-65)
Female 45 (23-65)
Race
Malay 34 (85)
Chinese 5 (12.5)
Indian 1 (2.5)
Treatment duration (month)
13-24 1 (2.5)
25-36 3 (7.5)
37-48 6 (15)
49-60 14 (35)
>61 16 (40)
Disease characteristic and 
treatment management
CML stage prior to IM
Chronic phase 37 (92.5)
Accelerated phase 3 (7.5)
Blast phase -
Treatment prior to IM
IFN 2 (5.0)
Hydroxyurea 21 (52.5)
No 17 (42.5)
CML stage in response to IM
Chronic phase 31 (77.5)
Accelerated phase 6 (15)
Blast phase 3 (7.5)
Hematologic response (HR)
Complete 34 (85)
Suboptimal 5 (12.5)
Loss of HR 1 (2.5)
Cytogenetic response (CR)
No 10 (25.0)
Major/ partial 4 (10.0)
Minor 11 (27.5)
Minimal 10 (25.0)
Complete but loss CyR 5 (12.5)
Resistance type
Primary resistance 35 (87.5)
Secondary resistance 5 (12.5)
CML, chronic myeloid leukemia; IM, imatinib mesylate.
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patients recruited was 2:3; mean age was 41
and 45 years, respectively. A slight predomi-
nance of the disease among females was
observed.
In this cross-sectional study, out of 40
Philadelphia chromosome positive CML
patients, mutations were detected in 13
(32.5%). Among these 13, 8 (70%) showed
T315I mutation. Another 5 patients showed
E255K (n=2), Y253H, M351T and V289F (1
each) mutations, respectively (Figure 1). The
remaining 27 patients who did not show tyro-
sine kinase domain mutation were subjected
to BCR-ABL gene amplification using FISH.
However, none of these 27 IM resistant
patients showed BCR-ABL gene amplification. 
Cytogenetic analysis of the bone marrow
samples was carried out in all these IM resist-
ant CML patients of whom 13 showed addition-
al chromosomal abnormalities apart from the
Philadelphia chromosome. The additional
chromosomal abnormalities included: trisomy
6 (n=1 patient), trisomy 8 (n=1), trisomy 10
(n=3), trisomy 16 (n=1) and trisomy 19
(n=2); monosomy 4 (n=2), del(15)(q22-26)
(n=1), del(17)(q23-25) (n=1) and i(17q10)
(n=1). However, a comparison of the ACA
(with or without ACA) with mutation (with or
without mutation) showed no significant dif-
ference (P=0.646).
Discussion
Reciprocal translocation between chromo-
somes 9 and 22, t(9:22)(q34;q11) is reported to
be the main factor contributing to CML. This
unique chromosome arrangement, known as
Philadelphia chromosome translocation, gen-
erates a BCR-ABL fusion gene that encodes a
constitutively active tyrosine kinase protein.
BCR-ABL fusion gene has now become the
universally accepted molecular signature and
the transforming event in CML pathogenesis.
The mRNA molecules transcribed from BCR-
ABL fusion gene usually contain one of the two
BCR-ABL junctions designated as b2a2
(e13a2) and b3a2 (e14a2). However, both
mRNAs translate into p210 Kda fusion protein
that may up-regulate the tyrosine kinase activ-
ity. This results in transformed cells that have
growth factor independent proliferation along
with decreased apoptosis, defective adhesion,
as well as genomic instability.
In the present study, we aimed to examine
the frequency distribution and nature of ABL
kinase domain mutation in CML patients treat-
ed with IM. The ability to detect mutations in
the BCR-ABL1 gene varies depending on the
technique used. In the present study, we used
the dHPLC technique for mutation analysis,
followed by sequencing to characterize the
mutations. The dHPLC assay provided a much
Article
Table 2. Cytogenetic and molecular test results of the chronic myeloid leukemia patients.
Cytogenetic and molecular results
Cytogenetics analysis (Bone marrow)
t(9;22)(q34;q11) only 27 (67.5)
Additional chromosomal abnormalities 13 (32.5)
Mutation at BCR-ABL gene
Absent 27 (67.5)
Present 13 (32.5)
Type of BCR-ABL TKD
T315I 8 (61.5)
E255K 2 (15.4)
M351T 1 (7.7)
Y253H 1 (7.7)
V289F 1 (7.7)
Occurrence of mutation 
Primary resistance 12 (92.3)
Secondary resistance 1 (7.7)
BCR-ABL gene fusion transcript
b3a2 31 (77.5)
b2a2 7 (17.5)
ela2 2 (5.0)
Figure 1. Sequencing analysis results of BCR-ABL gene showing: a) M351T mutation; and
b) T315I mutation. The circles indicate the nucleotide triplet that encodes the amino acid. 
No
n-c
om
me
rci
al 
us
e o
nly
[Hematology Reports 2012; 4:e23]
faster and less expensive method for mutation
screening. Taking advantage of the dHPLC
based assay for ABL mutational screening, as
well as a sequencing technique, we screened
40 patients who showed resistance to IM. Our
results showed that ABL kinase mutations are
a relevant mechanism of resistance to IM in
32.5% of Malaysian CML patients. 
Worldwide, researchers have detected quite
a number of mutations within the BCR-ABL
fusion domain among IM resistant CML
patients. In the present study on 40 Malaysian
CML patients showing IM resistance, we
detected a total of five different point muta-
tions all leading to amino acid substitutions.
Most of these mutations were found to be
located at the functional fraction of the BCR-
ABL fusion protein. Point mutations in ABL
kinase domain have been characterized into
two groups:13 1) mutations that impede contact
between BCR-ABL and IM; and 2) mutations
that alter the spatial conformation of the pro-
tein.7 The BCR-ABL structure contains two
flexible loop structures, the adenosine triphos-
phate-binding phosphate loop and the activa-
tion loop, which have specific arrangement in
the inactive conformation of BCR-ABL that sta-
bilizes the structure.9 According to Litzow, IM
mutations in these loops destabilize their
arrangement such that the kinase domain can-
not assume the inactive conformation
required for IM binding.9
Mutations located in the IM contact point
were reported to significantly reduce IM sensi-
tivity. Normally, these amino acids make
hydrogen bonds with IM; therefore, the muta-
tions occurring in one of the amino acids
might be causing resistance.2 This type of
mutation was found in 8 of our patients who
showed T315I mutation.  From the literature
reviewed, T315I was found to be the most com-
mon mutation reported worldwide and it also
happened to be the most common mutation
(70%) among the IM resistant CML patients in
the present study.14-16 In T315I mutation, a
polar amino acid that participated in hydrogen
bonds (threonine) is substituted with
isoleucine, which is the hydrophobic amino
acid. Thus, this single amino acid substitution
has been reported to interfere with a critical
hydrogen bond that forms between the ABL 1
kinase domain and IM.2 This allocated binding
prevented the IM inhibition of BCR-ABL1 and
conferred resistance to IM. 
The detection of BCR-ABL T315I mutation in
the present study is clinically relevant.
PolyPhen2 with a score of 0.999 using the
HumDiv model (http://genetics.bwh.harvard.
edu/pph2/) predicted the T315I mutation to be
possibly damaging. Indeed, residue 315 seems
to be critical for binding most adenosine
triphosphate-competitive kinase inhibitors
because BCR-ABL T315I confers resistance to
2nd generation tyrosine kinase inhibitors such
as nilotinib and many other drugs.17
Other than T315I mutation, V289F mutation
is also located at the IM binding site. In this
mutation, valine, a very hydrophobic amino
acid at position 289 is substituted with pheny-
lalanine that is also a very hydrophobic amino
acid. Like T315I, V289F was also predicted to
be possibly damaging when analyzed using
PolyPhen2 program with a score of 0.999 using
the HumDiv model (http://genetics.bwh.har-
vard.edu/pph2/).
Another mutation is M351T. In this muta-
tion at 351, amino acid methionine, a very
hydrophobic amino acid, is substituted with a
less hydrophobic amino acid (threonine).
Using the PolyPhen2 program, this type of
mutation was predicted to be possibly damag-
ing with a score of 1.00 using the HumDiv
model. In a study on a Singaporean population,
Ang et al. reported that M351T mutation was
uncommon in Asian IM resistant CML
patients, including Chinese, Malay, Indian and
other Asian ethnics origins, as no M351T
mutation was found in their study.18 However,
interestingly, one of our patients (of Malay
ethnic race) was found to have M351T muta-
tion within the IM binding site of BCR-ABL
kinase domain. 
Mutations were also found in the P-loop of
the BCR-ABL fusion domain. The residues of
nucleotide binding loop (p-loop) were reported
to be from 247 to 256.19 In our study, 2 patients
showed different p-loop mutations which were
Y253H and E255K mutations, respectively.
Both of these mutations were predicted to be
possibly damaging by using the PolyPhen2 pro-
gram. Patients with mutated p-loop BCR-ABL
domain have been reported to be 70 to 100-fold
less sensitive to IM compared to native BCR-
ABL.20 Other than that, mutations at the acti-
vation loop (a-loop) that include the residues
from 381 until 402 in ABL have also been
reported to cause different levels of IM sensi-
tivity among CML patients.21 However, none of
our patients harbored this type of mutation. 
Location of a mutation in a protein
sequence may reflect the effect to the protein
functions. Due to evolution, some proteins that
play a similar biological function in different
species may have significantly different pro-
tein sequences. However, part of the protein
sequences in most species is preserved to
retain the 3-dimensional structure, as well as
the structure that is critical for conducting the
biological function. Thus, these parts of pro-
tein sequences are usually conserved across
species.22 The multi-alignment of human ABL1
protein with its orthologs among various
species, using the ClustalX program (version
2.0.12), showed that all five mutations (T315I,
M351T, E255K, Y253H and V289F) that we
identified in our patients are conserved among
species in a highly conserved block (Figure 2).
From this, it is reasonable to presume that
these mutations may lead to alteration of the
BCR-ABL protein structure or important struc-
ture for its biological function that may affect
the action of IM on this protein.
The RT-PCR amplification of the TKD domain
of the BCR-ABL gene in this study was per-
formed by employing the primers described by
Soverini et al. which covers only codon 206-
421.12 Even though most of BCR-ABLmutations
reported worldwide occurred in the TKD, muta-
tions in the region of codon 421-500 which
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Figure 2. The multi-alignment of human ABL1 protein with its orthologs of various
species by using ClustalX program (version 2.0.12). All the mutations detected are high-
ly conserved among different species and located in a conserved block of amino acids.
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encode C-terminal lobe (i.e. E453K, Y456C and
K459Q) have also been reported.23 Apart from
the c-terminal, it has been reported that muta-
tions could also occur at the SH2-SH3 domain
(i.e. A196V, R47C and K84N).24 Unfortunately, in
the current study, these 2 regions were not
included in mutation screening. Had these 2
regions also been screened for mutations, it is
probable that the mutation frequency would
have been higher. Thus, for a better overview of
the BCR-ABL mutation, apart from the tyrosine
kinase domain, both c-terminal and SH2-SH3
domain regions should also be taken into con-
sideration. From these results, it is clear that
the BCR-ABL mutations contributed at least in
part to resistance to IM in 32.5% of our patients.
However, in those patients without kinase
domain mutations, it is likely that additional
factors may also contribute to resistance. In the
remaining 27 patients who did not show any
mutations, the contribution of BCR-ABL gene
amplification in mediating resistance was
investigated using FISH. But none of these 27
patients showed any BCR-ABL gene amplifica-
tion. It is presumed that in these 27 CML
patients, the mechanism of resistance to IM
might be due to BCR-ABL independent path-
ways. Another possibility could be the lower
sensitivity of the FISH method. The FISH probes
used are significantly larger than the BCR-ABL
fusion region. Consequently, the gene amplifi-
cation of BCR-ABL might not always be visible.
Therefore, the usage of quantitative PCR per-
formed on DNA is highly recommended to
detect BCR-ABL gene amplification. Our results
showed that BCR-ABL mutations are not the
only major mechanisms of resistance to IM in
Malaysian CML patients. Additional factors
besides kinase domain mutations may also con-
tribute to resistance to IM and this means we
need to find out what other predominant mech-
anisms of IM resistance are involved.
Conclusions
Different mutations confer different levels
of resistance and, therefore, detection as well
as characterization of TKD mutations is highly
important in order to guide therapy in CML
patients. Knowing the exact mutations respon-
sible for IM resistance will help to select the
most suitable TKIs for CML patients and
improve their management. Furthermore,
early detection of such mutations may allow
timely treatment intervention to prevent or
overcome resistance.
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